跳至主要内容
临床试验/EUCTR2012-005344-15-CZ
EUCTR2012-005344-15-CZ进行中(未招募)1 期

A Double Blind Study Aiming To Evaluate The Efficacy Of Bladder Instillation With Botulinum Toxin (200U) + TC-3 Gel In Comparison To Instillation With Botulinum Toxin (200U) + TC-3 Gel + DMSO, To DMSO Instillation and To Saline Instillation As Placebo In Overactive Bladder (OAB) Patients.

Adyton, s.r.o.0 个研究点开始时间: 2013年1月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • At screening:
  • 1. Female subject = 18 years of age
  • 2. Signed Independent Ethical Committee (IEC) approved informed consent is obtained from the subject (prior to any study-related procedures, including withdrawal of prohibited medication, if applicable).
  • 3. Subject is willing and able to complete the micturition diary and questionnaires correctly.
  • 4. Subject has symptoms of OAB for = 3 months prior to the Screening Visit.
  • At Randomization:
  • 1. Subject experiences at least 3 episodes of severe urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period.
  • 2. Subject experiences frequency of micturition on average = 8 times per 24-hour period during the 3-day micturition diary period.
  • 3. Subject is willing and able to complete the micturition diary and questionnaires correctly.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 35
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 13

排除标准

  • At Screening:
  • 1. The pregnancy test (HCG in urine) taken at screening visit is positive in women of childbearing positional.
  • 2. Female subject is breastfeeding, pregnant, intends to become pregnant during the study or of childbearing potential and sexually active and not practicing a highly reliable method of birth control.
  • 3. Subject in the opinion of the investigator has clinically significant Bladder Outlet Obstruction (BOO).
  • 4. Subject has post-void residual volume (PVR) >200 mL.
  • 5. Subject has neurogenic bladder.
  • 6. Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator (confirmed by a cough provocation test).
  • 7. Subject has an indwelling catheter or practices intermittent self-catheterization.
  • 8. Subject has diabetic neuropathy.
  • 9. Subject has evidence of a symptomatic urinary tract infection (urine Dipstick with nitrites present), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs.
  • 10. Subject receives non-drug treatment including electro-stimulation therapy (with the exception of a bladder training program or pelvic floor exercises which started more than 30 days prior to screening).
  • 11. Subject has any other clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study.
  • 12. Subject did not respond to previous anticholinergic treatment.
  • At Randomization:¨
  • 1. The pregnancy test (HCG in urine) taken at the Baseline Visit is positive in women of childbearing potential.
  • 2. Female subject is breastfeeding, pregnant, intends to become pregnant during the study or of childbearing potential is sexually active and not practicing a highly reliable method of birth. control.
  • 3. Subject has evidence of a symptomatic urinary tract infection (urine Dipstick with nitrites present)
  • 4. Subject has any other clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study.

研究者

发起方
Adyton, s.r.o.

相似试验